Jeong-Yun Choi

Prof. Jeong-Yun Choi


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2014 in Chemical Research in Toxicology
Verified
Journal Article
Open access
JKJinsook Kim
Jinsook Kim
ISInsil Song
Insil Song
AJAra Jo
Ara Jo
JSJoo-Ho Shin
Joo-Ho Shin
HCHana Cho
Hana Cho
JCJeong-Yun Choi
Jeong-Yun Choi
DNA polymerase (pol) ι is the most error-prone among the Y-family polymerases that participate in translesion synthesis (TLS). Pol ι can bypass various DNA lesions, e.g., N2-ethyl(Et)G, O6-methyl(Me)G, 8-oxo-7,8-dihydroguanine (8-oxoG), and an abasic site, though frequently with low fidelity. We assessed the biochemical effects of six reported genetic variations of human pol ι on its TLS properties, using the recombinant pol ι (residues 1–445) proteins and DNA templates containing a G, N2-EtG, O6-MeG, 8-oxoG, or abasic site. The Δ1–25 variant, which is the N-terminal truncation of 25 residues resulting from an initiation codon variant (c.3G > A) and also is the formerly misassigned wild-type, exhibited considerably higher polymerase activity than wild-type with Mg2+ (but not with Mn2+), coinciding with its steady-state kinetic data showing a ∼10-fold increase in kcat/Km for nucleotide incorporation opposite templates (only with Mg2+). The R96G variant, which lacks a R96 residue known to interact with the incoming nucleotide, lost much of its polymerase activity, consistent with the kinetic data displaying 5- to 72-fold decreases in kcat/Km for nucleotide incorporation opposite templates either with Mg2+ or Mn2+, except for that opposite N2-EtG with Mn2+ (showing a 9-fold increase for dCTP incorporation). The Δ1–25 variant bound DNA 20- to 29-fold more tightly than wild-type (with Mg2+), but the R96G variant bound DNA 2-fold less tightly than wild-type. The DNA-binding affinity of wild-type, but not of the Δ1–25 variant, was ∼7-fold stronger with 0.15 mM Mn2+ than with Mg2+. The results indicate that the R96G variation severely impairs most of the Mg2+- and Mn2+-dependent TLS abilities of pol ι, whereas the Δ1–25 variation selectively and substantially enhances the Mg2+-dependent TLS capability of pol ι, emphasizing the potential translational importance of these pol ι genetic variations, e.g., individual differences in TLS, mutation, and cancer susceptibility to genotoxic carcinogens.

11 April 2014 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
ISInsil Song
Insil Song
EKEun-Jin Kim
Eun-Jin Kim
IKIn-Hyeok Kim
In-Hyeok Kim
EPEun-Mi Park
Eun-Mi Park
KLKyung Eun Lee
Kyung Eun Lee
JCJeong-Yun Choi
Jeong-Yun Choi

4 March 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
MYMina Yeom
Mina Yeom
IKIn-Hyeok Kim
In-Hyeok Kim
JKJae-Kwon Kim
Jae-Kwon Kim
KKKyeongJin Kang
KyeongJin Kang
RERobert L. Eoff
Robert L. Eoff
JCJeong-Yun Choi
Jeong-Yun Choi

21 September 2016 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
JKJae-Kwon Kim
Jae-Kwon Kim
MYMina Yeom
Mina Yeom
JHJin-Kyung Hong
Jin-Kyung Hong
ISInsil Song
Insil Song
YLYoung-Sam Lee
Young-Sam Lee
JCJeong-Yun Choi
Jeong-Yun Choi

13 July 2012 in Chemical Research in Toxicology
Verified
Journal Article
Closed access
SLSeonhee Lim
Seonhee Lim
ISInsil Song
Insil Song
FGF. Peter Guengerich
F. Peter Guengerich
JCJeong-Yun Choi
Jeong-Yun Choi

Verified
Journal Article
Open access
PDF file
SHSangwoo Ham
Sangwoo Ham
KHKim heejeong
Kim heejeong
JYJin-Ha Yoon
Jin-Ha Yoon
KHKim Hyojung
Kim Hyojung
BSBo Reum Song
Bo Reum Song
YLYunjong Lee
Yunjong Lee
The motor and nonmotor symptoms of Parkinson’s disease (PD) correlate with the formation and propagation of aberrant α-synuclein aggregation. This protein accumulation is a pathological hallmark of the disease. Our group recently showed that peucedanocoumarin III (PCIII) possesses the ability to disaggregate β sheet aggregate structures, including α-synuclein fibrils. This finding suggests that PCIII could be a therapeutic lead compound in PD treatment. However, the translational value of PCIII and its safety information have never been explored in relevant animal models of PD. Therefore, we first designed and validated a sequence of chemical reactions for the large scale organic synthesis of pure PCIII in a racemic mixture. The synthetic PCIII racemate facilitated clearance of repeated β sheet aggregate (β23), and prevented β23-induced cell toxicity to a similar extent to that of purified PCIII. Given these properties, the synthetic PCIII’s neuroprotective function was assessed in 6-hydroxydopamine (6-OHDA)-induced PD mouse models. The PCIII treatment (1 mg/kg/day) in a 6-OHDA-induced PD mouse model markedly suppressed Lewy-like inclusions and prevented dopaminergic neuron loss. To evaluate the safety profiles of PCIII, high dose PCIII (10 mg/kg/day) was administered intraperitoneally to two-month-old mice. Following 7 days of PCIII treatment, PCIII distributed to various tissues, with substantial penetration into brains. The mice that were treated with high dose PCIII had no structural abnormalities in the major organs or neuroinflammation. In addition, high dose PCIII (10 mg/kg/day) in mice had no adverse impact on motor function. These findings suggest that PCIII has a relatively high therapeutic index. Given the favorable safety features of PCIII and neuroprotective function in the PD mouse model, it may become a promising disease-modifying therapy in PD to regulate pathogenic α-synuclein aggregation.